T cell-NF-κB activation is required for tumor control in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

T cell-NF-κB activation is required for tumor control in vivo

Published:2015-01-20 Issue:1 Volume:3 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Barnes Sarah E,Wang Ying,Chen Luqiu,Molinero Luciana L,Gajewski Thomas F,Evaristo Cesar,Alegre Maria-Luisa

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-014-0045-x.pdf

Reference61 articles.

1. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T: Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014, 14(2):135–146.

2. Chakraborty AK, Weiss A: Insights into the initiation of TCR signaling. Nat Immunol 2014, 15(9):798–807.

3. Abe BT, Shin DS, Mocholi E, Macian F: NFAT1 supports tumor-induced anergy of CD4(+) T cells. Cancer Res 2012, 72(18):4642–4651.

4. Chow CW, Rincon M, Davis RJ: Requirement for transcription factor NFAT in interleukin-2 expression. Mol Cell Biol 1999, 19(3):2300–2307.

5. Xiao G, Deng A, Liu H, Ge G, Liu X: Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A 2012, 109(38):15419–15424.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NF-κB subunits RelA and c-Rel selectively control CD4+ T cell function in multiple sclerosis and cancer;Journal of Experimental Medicine;2024-04-02

2. The NF-κB RelA transcription factor is not required for CD8+ T-cell function in acute viral infection and cancer;Frontiers in Immunology;2024-03-05

3. Intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses;2023-11-05

4. The transcription factor IRF4 determines the anti-tumor immunity of CD8+ T cells;iScience;2023-11

5. Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy;Cancer Immunology Research;2023-10-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3